napabucasin

Napabucasin is an orally administered small molecule cancer stemness inhibitor with potential antineoplastic activity. It primarily targets and inhibits the signal transducer and activator of transcription 3 (STAT3) pathway, which is overactivated in many cancers and plays a key role in cancer stem cell-mediated tumor propagation. By inhibiting STAT3 and other pathways involved in cancer cell "stemness," napabucasin aims to suppress the growth of both cancer stem cells (CSCs) and heterogeneous tumor cells. This mechanism may help overcome resistance to conventional chemotherapies. Napabucasin has been investigated as monotherapy and in combination with standard chemotherapy agents for various solid tumors including colorectal carcinoma, pancreatic adenocarcinoma, gastric cancer, liver cancer, glioblastoma, malignant melanoma, non-small cell lung cancer (NSCLC), gastrointestinal cancers, and other solid tumors[1][3][4].

Other names

napabucasin2-acetylfuro-1,4-naphthoquinone2-acetylnaphtho[2,3-b]furan-4,9-dione2-acetylbenzo[f][1]benzofuran-4,9-dioneNapabucasinaNapabucasine